HOLX Hologic Inc

Price (delayed)

$70.93

Market cap

$17.69B

P/E Ratio

11.57

Dividend/share

N/A

EPS

$6.13

Enterprise value

$18.49B

Hologic, Inc. is a medical technology company primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging. In late November 2013, activist investor Carl Icahn ...

Highlights
Hologic's quick ratio has increased by 27% QoQ and by 21% YoY
HOLX's equity is up by 26% year-on-year and by 6% since the previous quarter
Hologic's net income has decreased by 19% YoY and by 10% QoQ
The EPS has declined by 17% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of HOLX
Market
Shares outstanding
249.38M
Market cap
$17.69B
Enterprise value
$18.49B
Valuations
Price to earnings (P/E)
11.57
Price to book (P/B)
3.7
Price to sales (P/S)
3.31
EV/EBIT
9.08
EV/EBITDA
7.49
EV/Sales
3.43
Earnings
Revenue
$5.39B
EBIT
$2.04B
EBITDA
$2.47B
Free cash flow
$2.61B
Per share
EPS
$6.13
Free cash flow per share
$10.37
Book value per share
$19.17
Revenue per share
$21.43
TBVPS
$18.46
Balance sheet
Total assets
$9.51B
Total liabilities
$4.72B
Debt
$3.09B
Equity
$4.79B
Working capital
$2.58B
Liquidity
Debt to equity
0.65
Current ratio
2.97
Quick ratio
2.38
Net debt/EBITDA
0.32
Margins
EBITDA margin
45.8%
Gross margin
64.2%
Net margin
28.8%
Operating margin
37.7%
Efficiency
Return on assets
17.1%
Return on equity
35.7%
Return on invested capital
45.9%
Return on capital employed
24.8%
Return on sales
37.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOLX stock price

How has the Hologic stock price performed over time
Intraday
0.54%
1 week
4.49%
1 month
-9.52%
1 year
9.12%
YTD
-7.35%
QTD
-7.67%

Financial performance

How have Hologic's revenue and profit performed over time
Revenue
$5.39B
Gross profit
$3.46B
Operating income
$2.03B
Net income
$1.55B
Gross margin
64.2%
Net margin
28.8%
The company's net margin fell by 20% YoY and by 8% QoQ
The operating margin has contracted by 20% YoY and by 7% from the previous quarter
Hologic's net income has decreased by 19% YoY and by 10% QoQ
Hologic's operating income has decreased by 19% YoY and by 8% QoQ

Growth

What is Hologic's growth rate over time

Valuation

What is Hologic stock price valuation
P/E
11.57
P/B
3.7
P/S
3.31
EV/EBIT
9.08
EV/EBITDA
7.49
EV/Sales
3.43
The EPS has declined by 17% year-on-year and by 9% since the previous quarter
The stock's price to earnings (P/E) is 8% more than its last 4 quarters average of 10.7
HOLX's price to book (P/B) is 26% lower than its 5-year quarterly average of 5.0 and 14% lower than its last 4 quarters average of 4.3
HOLX's equity is up by 26% year-on-year and by 6% since the previous quarter
HOLX's price to sales (P/S) is 11% lower than its 5-year quarterly average of 3.7 and 2.6% lower than its last 4 quarters average of 3.4

Efficiency

How efficient is Hologic business performance
The ROE has contracted by 44% YoY and by 15% from the previous quarter
Hologic's return on assets has decreased by 34% YoY and by 13% QoQ
The return on sales has declined by 20% year-on-year and by 7% since the previous quarter
HOLX's return on invested capital is down by 19% year-on-year and by 7% since the previous quarter

Dividends

What is HOLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOLX.

Financial health

How did Hologic financials performed over time
The total assets is 102% higher than the total liabilities
Hologic's quick ratio has increased by 27% QoQ and by 21% YoY
The total assets has increased by 18% YoY and by 2.5% QoQ
The company's debt is 35% lower than its equity
HOLX's equity is up by 26% year-on-year and by 6% since the previous quarter
The company's debt rose by 12% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.